Inactive occupational status and low educational level were associated with pain, late disease onset, and greater number of affected areas in patients with hidradenitis suppurativa.
Certain disease-specific factors may affect educational level and occupational status in patients with hidradenitis suppurativa (HS), according to study findings published in Actas Dermo-Sifiliograficas.
As a chronic, inflammatory, and relapsing skin disease, HS is a painful condition associated with physical and psychiatric symptoms. The economical impact of the disease has also been demonstrated, with prior research showing that patients with HS have significantly lower income growth and a lower annual income compared with the general population.
“Many patients experience embarrassment, shame, and social isolation because of their HS. It is then not surprising that HS could have a negative impact on educational level and labor activity,” said the study authors. “Some studies mentioned the negative impact of HS on daily activity, but none assessed the negative impact of HS on patients' careers.”
They conducted a cross-sectional analysis of patients with HS seen at a tertiary hospital in Badalona, Spain, between September 2017 and September 2018, to assess whether any disease-specific variables influenced occupational status and educational level.
The study cohort participated in the European Registry of HS, a standardized questionnaire designed by the European HS Foundation, with the following variables examined:
Ninety-eight patients with HS (median [IQR] age, 39.7 [30.1-47.2] years; median age of onset of HS, 19 [15.0-27.7] years; median delay in HS diagnosis, 8 [3-17]years; 65.3% female) were included in the study. Overall, 70.1% were overweight or obese, 79.4% had at least 1 comorbidity, and 23.7%, 21.5%, and 9.7% had moderate, severe, and extreme HS severity according to the DLQI, respectively.
Moreover, 23.1% and 76.8% of patients were included in the university and nonuniversity studies group, respectively, and 63.3% were employed or students.
Compared with patients of the university studies group, those of the nonuniversity group more frequently reported 3 affected areas (22.5% vs 4.8%; P = .049), a mean (SD) higher number of painful days (8.5 [8.8] vs 4.6 [4.8]; P = .048), and a higher score on the VAS scale (6.7 [2.8] vs 5.0 [3.3]; P = .031).
Patients from the inactive group showed a significantly increased mean number of painful days (11.2 [10.4] vs 5.7 [6.2]; P = .004), greater incidence of depression (61.3% vs 27.4%; P = .002), and a higher mean BMI (32.3 [9.1] vs 28.4 [6.4]; P = .016) compared with the active group. Late disease onset was found to be significantly associated with being in the inactive vs active group (26.7% vs 6.5%; P = .026).
No significant differences between severity scales of HS and educational level or occupational status were found.
Researchers concluded that physicians have to take into account the significant relation shown regarding poor pain control with lower educational level and inactive occupational status since it could be a modifiable variable of the disease. Limitations of the analysis included its cross-sectional and single-center study design.
Reference
Barboza-Guadagnini L, Podlipnik S, Fuertes I, Morgado-Carrasco D, Bassas-Vila J. Pain and late-onset of hidradenitis suppurativa can have a negative influence on occupational status and educational level. A cross-sectional study. Actas Dermosifiliogr (Engl Ed). Published online August 27, 2022. doi:10.1016/j.ad.2022.08.016
Health Equity and Access Weekly Roundup: May 11, 2024
May 11th 2024This week's topics include frameworks for improving health equity nationwide, addressing social determinants of health, discussing CMS's Medicare rules, investigating breast cancer treatment refusal, and exploring HIV and major depressive disorder in underrepresented groups.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Navigating Medicare's Part D Subsidy Program to Achieve Value-Based Care
May 26th 2023On this episode of Managed Care Cast, we speak with the lead researcher from a study published in the May 2023 issue of The American Journal of Managed Care® about the impact of low-income subsidies on the uptake and equitable use of expensive orally administered antimyeloma therapy.
Listen
Following Roe v Wade Overturn, Research Focuses on Male Contraceptives
May 6th 2024Stephanie T. Page, MD, PhD, UW Medicine Diabetes Institute, presented on ongoing research and growing interest in new male contraceptive options, such as an oral pill and a hormonal transdermal gel, at the American Urological Association 2024 Annual Meeting.
Read More